DealBio
Last updated August 25, 2026

Dx4Life

Developing a rapid swab test to match IVF hormone treatment to a woman's genetics.

FertilityPoint-of-care diagnosticsPrecision medicine

clinics choose between two hormone treatments when stimulating a patient's ovaries before egg collection. With no routine marker showing which treatment best suits each patient, the decision largely depends on cost and clinical practice.

Dx4Life is developing Dx4IVF, a cheek-swab test that reads a variant in the receptor carrying the hormone signal to the ovaries. The clinic receives a visible result in under an hour, allowing the clinician to prescribe during the same appointment.

WebsiteLinkedIn

Key Investor Signals

Raised SEK 6.4M in a first round led by Gobia Enterprises

Dx4Life closed its first funding round in November 2024. led the round, with participation from and Taxam AB, to support certification and commercial launch.

International patent application filed for Dx4IVF

Dx4Life has applied for covering its rapid product.

Won Lund University's top 2025 Future Innovations prize

Founder Yvonne Lundberg Giwercman received the award for developing Dx4IVF.

Other Positive Signals

  • A peer-reviewed study of 1,466 women found a 40% cumulative among women whose treatment matched their genotype, compared with 29% among non-genotyped controls.
  • Dx4IVF agreed with DNA sequencing in 91 of 100 patient samples, with 100% specificity and results in under an hour.
  • Became the first company to emerge from 's Innovation Platform.
  • Joined the incubator to prepare Dx4IVF for commercialization.

Team

Yvonne Lundberg Giwercman

Founder and CEO

  • Professor at 's Faculty of Medicine since 2018.
  • Has led the Molecular Genetic Reproductive Medicine research group at Lund University since 2009.
  • Has published 88 peer-reviewed journal articles on hormone receptor genetics in reproduction and cancer.
  • Holds a PhD in Clinical Genetics from in Stockholm.

Product

Dx4IVF is a genotyping test designed for fertility clinics. It uses a cheek swab to identify an variant associated with different responses to hormones, producing a visible result during the patient's appointment.

Guides treatment before stimulation begins

Most genetic testing in IVF analyses embryos after fertilization. Dx4IVF tests the patient beforehand, allowing the result to guide which hormone treatment is prescribed.

Turns a cheek swab into a genetic result

The test adapts an isothermal amplification method to identify the FSHR N680S variant without conventional DNA-sequencing equipment.

Designed for the existing clinic workflow

The sample is heated twice and read through a colour change. The process takes under an hour, requires only a heating block, and can also support egg donation or egg-freezing treatments.

Market Overview

is one of the first major steps in IVF and requires clinicians to choose between recombinant and human menopausal gonadotropin. Current treatment decisions largely reflect availability, convenience and cost. A rapid biomarker used before stimulation could make that decision patient-specific.

Dx4Life sells directly to fertility clinics, where the test can be used before IVF, egg donation or egg freezing. The buyer already controls the prescription and treatment workflow, giving the company a direct route into a large and growing fertility market.

One in six adults experience infertility
17.5%

Share of the global adult population estimated to experience infertility during their lifetime.

Assisted-reproduction cycles performed each year
4 million

Estimated annual number of cycles worldwide. Each ovarian-stimulation cycle requires a hormone-treatment decision.

Europe is the largest IVF market
36.7%

Europe's share of worldwide IVF market revenue in 2023.

Global IVF market in 2026
$30.5B

Forecast to reach $37.4B by 2030, adding approximately $6.9B at a 5.5% annual growth rate.

Comparable Outcomes

Reproductive genetic testing for IVF clinics

Igenomix

Acquired by Vitrolife for €1.25B

built a genetic testing business selling directly to IVF clinics through a global network of laboratories, covering reproductive and personalized medicine. Its , which read the genetics of an embryo before transfer, were its largest source of revenue. completed the acquisition of Igenomix in November 2021 for €1.25B.

Point-of-care molecular diagnostics

Mesa Biotech

Acquired by Thermo Fisher for $450M

developed the Accula platform, moving molecular testing from centralized laboratories into clinics. completed the acquisition in February 2021 for approximately $450M in cash, with up to $100M tied to milestones.

Genetic testing that guides treatment

Genomic Health

IPO at approx. $292M, later acquired for $2.8B

developed the Oncotype DX assays to estimate cancer-recurrence risk and predict whether a patient would benefit from chemotherapy. Genomic Health listed on Nasdaq in October 2005, valuing the company at roughly $292M. completed its acquisition in November 2019 for $2.8B.

Have a question about Dx4Life?

Ask DealBio. We may research the answer or share selected questions with the company.

Sources

This profile was built from public company materials, ecosystem sources, market references, and professional profiles.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.